# Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

> **NCT00478725** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 10 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** GW786034, oral
- **DRUG:** GW786034, IV
- **DRUG:** GW786034, radiolabeled oral

## Key facts

- **NCT ID:** NCT00478725
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-18
- **Primary completion:** 2008-07-01
- **Final completion:** 2008-07-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478725, "Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00478725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*